Regeneron Pharmaceuticals (REGN) announced earnings for second quarter that beat the Street estimates.
The company's bottom line totaled $1.392 billion, or $12.81 per share. This compares with $1.432 billion, or $12.41 per share, last year.
Excluding items, Regeneron Pharmaceuticals reported adjusted earnings of $1.424 billion or $12.89 per share for the period.
Analysts on average had expected the company to earn $8.43 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period rose 3.6% to $3.676 billion from $3.547 billion last year.
Regeneron Pharmaceuticals earnings at a glance (GAAP) :
-Earnings: $1.392 Bln. vs. $1.432 Bln. last year.-EPS: $12.81 vs. $12.41 last year.-Revenue: $3.676 Bln vs. $3.547 Bln last year.
Leonard S. Schleifer, CEO of Regeneron, said: "Regeneron had a strong quarter, marked by significant growth in U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo along with multiple regulatory approvals.”
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.